Answers are grounded in this paper and cite their sources.
Pyruvate kinase M2 (PKM2) is increasingly recognized as a multifunctional regulator in cancer rather than merely a glycolytic enzyme. Its biological functions are influenced not only by expression level but also by oligomeric state, post‑translational regulation and subcellular or extracellular localization. In the present review, the current evidence on the role of PKM2 in cancer progression, metabolic adaptation, tumor microenvironment remodeling and therapeutic resistance is summarized. In defined cancer models, reduced cytosolic PKM2 activity redirects glycolytic intermediates toward biosynthetic or antioxidant pathways during nutrient deprivation or oxidative stress. Nuclear PKM2 participates in transcription‑associated programs related to hypoxia adaptation, inflammatory signaling, programmed death ligand 1 regulation and therapy tolerance, although the precise catalytic and non‑catalytic mechanisms of nuclear PKM2 remain incompletely defined. Extracellular PKM2 is implicated in tumor‑stromal communication, including effects on monocytes, macrophages and fibroblasts; its interpretation depends on its cellular source, extracellular form and recipient cell. In the present review, unresolved issues, including the context‑dependent requirement for PKM2 in tumor maintenance and the limitations of total PKM2 abundance as a biomarker are also examined. Overall, PKM2 should be evaluated according to its molecular state, cellular localization and tumor context when considering biomarker development and therapeutic strategies in cancer.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: